NDAORALCAPSULEPriority Review
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
Priority Review
NIMOTOP (nimodipine) by R-Pharm US is mechanism of action nimodipine is a calcium channel blocker. First approved in 1988.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIMOTOP (nimodipine) is an oral calcium channel blocker approved in 1988 for the treatment of cerebral vasospasm following subarachnoid hemorrhage (SAH). It inhibits calcium ion influx into vascular smooth muscle cells, with preferential effect on cerebral arteries due to high lipophilicity and blood-brain barrier penetration. The exact mechanism by which nimodipine improves neurological outcomes in SAH patients remains incompletely understood, as arteriographic studies have not demonstrated prevention or relief of vasospasm.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and transition focus.
Mechanism of Action
Mechanism of Action Nimodipine is a calcium channel blocker. The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Acupuncture Combined With Nimodipine for Prevention of Post-stroke Dementia
Started Feb 2021
Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1
36 enrolled
AIDS Dementia ComplexHIV Infections
Worked on NIMOTOP at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.